Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 1, 2009, Pages 56-62

  Hartwell, Debbie ^a   Shepherd, Jonathan ^a  

^a NONE

Author keywords

Mild hepatitis C; Non pegylated interferon alfa; Pegylated interferon alfa; Ribavirin; Systematic review

Indexed keywords

MILD HEPATITIS C; NON-PEGYLATED INTERFERON-ALFA; PEGYLATED INTERFERON-ALFA; RIBAVIRIN; SYSTEMATIC REVIEW;

AMIDES; GLYCOPROTEINS; INFORMATION SERVICES; POLYETHYLENE GLYCOLS; RISK ANALYSIS;

ANTIBIOTICS;

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEVER; GENOTYPE; HEADACHE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; MONOTHERAPY; MYALGIA; QUALITY OF LIFE; RISK FACTOR; SENSITIVITY ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE COURSE; DRUG COMBINATION; GENETICS; HOSPITALIZATION; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 60749112820     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309090084     Document Type: Article

References (25)

1. Arora S, O'Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: Impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21:406-412.
2. Behler CM, Vittinghoff E, Lin F, et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007;44:1375-1383. (Pubitemid 46717302)
3. Cheng PN, Chow NH, Hu SC, et al. Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Dig Liver Dis. 2002;34:851-856.
4. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa- 2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459. (Pubitemid 38988594)
5. Department of Health. Hepatitis C action plan for England. London: Department of Health; 2004.
6. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209-212.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C:Arandomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
8. Harris KA, Gilham C, Mortimer PP, et al. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol. 1999;58:127-131. (Pubitemid 29226854)
9. Kim TH, Kim KA, Lim YS, et al. Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. Intervirology 2005;48:230-238.
10. Mangia A, Villani MR, Minerva N, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: A randomized controlled trial. J Hepatol. 2001;34:441-446. (Pubitemid 32240825)
11. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet. 1999;354:1896-1900.
12. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut. 2001;48:707-713.
13. National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. NICE Technology Appraisal Guidance 106. London: National Institute for Health and Clinical Excellence; 2006.
14. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd ed. York: York Publishing Services Ltd; 2001.
15. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology. 1996;161: 778-789. (Pubitemid 26334273)
16. Poynard T, McHutchison J, Goodman Z, et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31:211-218. (Pubitemid 30033709)
17. Reichard O, Norkrans G, Fryden A, et al. Randomised, doubleblind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83-87. (Pubitemid 28026633)
18. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut. 2004;53:451-455.
19. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon a- 2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2004;8:1-140.
20. Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1-205.
21. Strader DB, Wright T, Thomas DL et al. American Association for the Study of Liver Diseases (AASLD) practice guidelines. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
22. Verbaan HP, Widell HE, Bondeson TL, et al. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol. 2002;14:627-633.
23. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha- 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522-527. (Pubitemid 41096640)
24. Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: Amulticentre randomized controlled trial. J Viral Hepat. 2005;12:58-66. (Pubitemid 40188775)
25. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-1732. (Pubitemid 39575851)